Equities

PeptiDream Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

PeptiDream Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,566.00
  • Today's Change-9.00 / -0.57%
  • Shares traded389.10k
  • 1 Year change-36.16%
  • Beta0.5092
Data delayed at least 15 minutes, as of Jul 03 2025 03:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

  • Revenue in JPY (TTM)46.68bn
  • Net income in JPY14.82bn
  • Incorporated2006
  • Employees621.00
  • Location
    PeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
  • Phone+81 442701300
  • Websitehttps://www.peptidream.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Healios KK588.00m-4.37bn45.22bn65.00--22.42--76.91-46.81-46.816.4219.270.0366--2.639,046,154.00-27.16-24.31-43.03-30.7773.30---743.03-2,817.04---1.590.7739--362.8144.46-10.78--19.31--
Shin Nippon Biomedical Laboratories Ltd32.41bn4.92bn59.66bn1.44k12.111.497.981.84118.30118.30778.58961.350.38421.245.3022,572,290.005.779.908.4014.8252.3352.6815.0123.350.6946--0.463330.4922.5517.36-10.9614.0754.7958.49
Heartseed Inc2.64bn614.54m60.87bn39.00101.488.08164.7623.0626.5826.58117.83333.720.4047--9.6067,685,900.009.42--9.89------23.28--19.27157.480.0004--153.42--44.84------
Takara Bio Inc45.04bn1.04bn96.09bn1.78k92.310.83217.832.138.658.65374.03959.190.36531.563.5725,317,030.000.88168.660.93849.7057.8863.762.4117.166.34--0.009431.403.535.44-29.59-22.8820.4616.27
GNI Group Ltd22.98bn-886.60m166.78bn867.00--4.86--7.26-17.71-17.71458.85679.050.34412.054.5826,509,560.00-3.925.12-4.986.2375.8083.27-11.4011.231.96-2.140.1530.00-9.2225.96-86.4343.2820.19--
SanBio Co Ltd0.00-4.27bn167.94bn29.00--88.62-----61.10-61.100.0026.310.00----0.00-98.97-47.32-112.89-57.01-----------4.450.4276-------9.02---46.04--
Peptidream Inc46.68bn14.82bn210.94bn621.0014.213.8212.414.52114.17114.17360.07424.190.62094.289.9075,176,500.0019.7213.4922.5515.7973.8970.0531.7526.454.7872.920.25740.0062.57--394.59------
Data as of Jul 03 2025. Currency figures normalised to PeptiDream Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

30.41%Per cent of shares held by top holders
HolderShares% Held
M&G Investment Management Ltd.as of 15 Apr 202511.05m8.50%
Asset Management One Co., Ltd.as of 13 Sep 20245.90m4.54%
Taiyo Pacific Partners LPas of 30 Jan 20255.07m3.90%
Baillie Gifford & Co.as of 31 May 20253.66m2.82%
Nomura Asset Management Co., Ltd.as of 05 Jun 20253.35m2.58%
The Vanguard Group, Inc.as of 04 Jun 20253.10m2.39%
Norges Bank Investment Managementas of 31 Dec 20242.84m2.18%
Nikko Asset Management Co., Ltd.as of 06 Jun 20251.71m1.32%
Daiwa Asset Management Co. Ltd.as of 30 May 20251.43m1.10%
Alma Capital Investment Management SA (UK)as of 31 Dec 20241.42m1.09%
More ▼
Data from 31 Dec 2024 - 18 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.